Related Experiment Video
Updated: Mar 5, 2026

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Sarcomas With CIC-rearrangements Are a Distinct Pathologic Entity With Aggressive Outcome: A Clinicopathologic and
Cristina R Antonescu1, Adepitan A Owosho, Lei Zhang
1Departments of *Pathology †Surgery ¶Medicine, Memorial Sloan Kettering Cancer Center, New York, NY ‡Department of Pathology, Erciyes University, Kayseri, Turkey §Department of Pathology, Shuang Ho Hospital, Taipei Medical University, Taipei ∥Department of Anatomical Pathology, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan #Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.
Abstract:
CIC-DUX4 gene fusion, resulting from either a t(4;19) or t(10;19) translocation, is the most common genetic abnormality detected in EWSR1-negative small blue round cell tumors. Following their discovery it was debated if these tumors should be classified as variants of Ewing sarcoma (ie, atypical Ewing sarcoma) or as a stand-alone pathologic entity. As such the WHO classification temporarily grouped the CIC-rearranged tumors under undifferentiated sarcomas with round cell phenotype, until further clinical evidence was available. However, most studies reported so far include small series with limited follow-up information, which preclude a more definitive assessment. The present work investigates the clinicopathologic features of a large cohort of sarcomas with CIC gene rearrangement, to define their clinical presentation, morphologic spectrum, and outcome. Our study further examines the overall survival of the CIC-positive cohort compared with a control group of EWSR1-rearranged Ewing sarcoma matched for age and stage. The study cohort included 115 patients, with a mean age of 32 years and a slight male predominance. Most tumors occurred in the soft tissue (86%), predominantly deep-seated and equally divided among trunk and extremity, followed by visceral locations (12%) and rarely in the bone (3%). Microscopically, most tumors showed round to ovoid cytomorphology but half of the cases showed also focal areas of spindling and epithelioid/rhabdoid phenotype, with frequent myxoid stromal changes. Variable CD99 reactivity was seen in 84% cases, with a diffuse pattern only in 23% of cases, whereas nuclear WT1 was seen in 92%. A CIC-DUX4 fusion was detected in 57% of cases, with either DUX4 on 4q35 (35%) or on 10q26 in 25 (22%) cases. No FOXO4 gene rearrangements were present in 39 cases tested. Clinical follow-up was available in 57 patients, with a 5-year survival of 43%, which was significantly lower than the 77% 5-year survival in the control Ewing sarcoma group (P=0.002). Our findings show that CIC-DUX4 sarcomas occur most commonly in young adults within the somatic soft tissues, having a wide spectrum of morphology including round, epithelioid and spindle cells, and associated with an aggressive clinical course, with an inferior overall survival compared with Ewing sarcoma. The results support the classification of CIC-rearranged tumors as an independent molecular and clinical subset of small blue round cell tumors distinct from Ewing sarcoma.
Insights
CIC-DUX4 gene fusions are common in EWSR1-negative small blue round cell tumors. These sarcomas, distinct from Ewing sarcoma, show aggressive behavior and poorer survival rates in young adults.
Area of Science:
- Oncology
- Genetics
- Pathology
Background:
- CIC-DUX4 gene fusions are the most common abnormality in EWSR1-negative small blue round cell tumors.
- Previous classifications debated whether these are Ewing sarcoma variants or distinct entities.
- Limited data existed on their clinical presentation, morphology, and outcomes.
Purpose of the Study:
- To investigate the clinicopathologic features of a large cohort of CIC-rearranged sarcomas.
- To define their clinical presentation, morphologic spectrum, and patient outcomes.
- To compare the survival of CIC-rearranged sarcomas with EWSR1-rearranged Ewing sarcoma.
Main Methods:
- Analysis of 115 patients with CIC gene rearrangement.
- Morphologic evaluation, including cytomorphology and immunohistochemistry (CD99, WT1).
- Genetic analysis for CIC-DUX4 fusion and comparison with a matched Ewing sarcoma cohort.
Main Results:
- Most tumors occurred in soft tissues of young adults (mean age 32 years).
- Morphology varied, including round, epithelioid, and spindle cells with myxoid changes.
- CIC-DUX4 fusion detected in 57% of cases.
- 5-year survival was 43% for CIC-rearranged sarcomas versus 77% for Ewing sarcoma (P=0.002).
Conclusions:
- CIC-DUX4 sarcomas present a distinct clinicopathologic and molecular entity.
- These tumors exhibit aggressive behavior and inferior survival compared to Ewing sarcoma.
- The findings support classifying CIC-rearranged tumors as a separate subset of small blue round cell tumors.
Related Concept Videos
Abnormal Proliferation
Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

